Expert Outlook: Amicus Therapeutics Through The Eyes Of 4 Analysts
Portfolio Pulse from Benzinga Insights
Amicus Therapeutics (NASDAQ:FOLD) received mixed ratings from 4 analysts, with 1 bullish and 3 somewhat bullish ratings. The average 12-month price target is $18.0, down 3.59% from the previous $18.67. Analysts have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Amicus Therapeutics, a biotechnology company, reported a 34.04% revenue growth rate but faces challenges with a high debt-to-equity ratio and below-average ROE.
October 11, 2024 | 7:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Amicus Therapeutics received mixed analyst ratings with a 12-month price target of $18.0, a decrease from $18.67. The company reported strong revenue growth but faces challenges with high debt and below-average ROE.
The mixed analyst ratings and lowered price target suggest a neutral short-term impact on Amicus Therapeutics' stock. While the company shows strong revenue growth, its high debt-to-equity ratio and below-average ROE may offset positive sentiment. The overall analyst sentiment is somewhat bullish, but the decrease in the average price target indicates tempered expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100